Particularly, anti-apoptotic Bcl-xL was significantly downregulated while pro-apoptotic Bcl-xS was upregulated after pladienolide B treatment in the preclinical-xenograft GBM model (Fig. S5g), GBM cells [U-87/U-118 MG cells (Fig. S5h) and primary-GBM cell cultures (Fig. S5i)], but not in primary non-tumor cell cultures (Fig. S5j). The gene discussed is BCL2L1; the disease is glioblastoma.